Neoplasms

Blood and Lymph Conditions

All Conditions

Leukemia

Hematologic Neoplasms

Hematologic Diseases

Anti-Infective Agents

Antineoplastic Agents

All Drugs and Chemicals

Cytarabine

Antimetabolites

Antiviral Agents

Immunosuppressive Agents

Immunologic Factors

CP-4055

Francis J Giles, MD

Patients with refractory or relapsed hematologic malignancies will receive CP-4055 intravenously(IV) on Day 1-5 every three weeks until complete response or disease worsening/progressing

This is a multicentre clinical study conducted in the USA and in Europe. It is an open label, dose escalation study designed to characterize the safety, tolerability, pharmacokinetics (PK), and efficacy of CP-4055 as a single agent when administered as a 2 hours intravenous (IV) or a continuous IV (CIV) infusion administered daily for 5 days in a 21-day cycle, either alone or with idarubicin IV, in patients with refractory/relapsed hematologic malignancies who have either failed potentially curative therapy or are considered unsuitable for standard therapy.

In a second phase of the study the efficacy of single agent CP-4055 in patients with AML may be assessed.

It is intended that patients receive a minimum of two cycles of therapy in the absence of unacceptable toxicity or significant disease progression.

A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies

Clavis Pharma

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies	NCT00405743	Hematologic Mal... AML	CP-4055 CP-4055	18 Years -	Clavis Pharma
A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies	NCT00405743	Hematologic Mal... AML	CP-4055 CP-4055	18 Years -	Clavis Pharma

Spots Global Cancer Trial Database for amm

Every month we try and update this database with for amm cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for amm

Every month we try and update this database with for amm cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for amm cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.